- Home
- CE vs LEGN Comparison
CE vs LEGN Comparison
Compare CE & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CE | LEGN |
|---|---|---|
| Founded | 1918 | 2014 |
| Country | United States | United States |
| Employees | 11434 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.9B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CE | LEGN |
|---|---|---|
| Price | $48.24 | $29.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $64.29 | $61.33 |
| AVG Volume (30 Days) | 1.4M | ★ 3.3M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | ★ 23.62 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $9,544,000,000.00 | N/A |
| Revenue This Year | $3.14 | $42.68 |
| Revenue Next Year | $2.83 | $30.52 |
| P/E Ratio | $124.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.13 | $16.24 |
| 52 Week High | $70.70 | $45.30 |
Technical Indicators
Market Signals| Indicator | CE | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.13 | 46.96 |
| Support Level | $47.67 | $24.94 |
| Resistance Level | $48.41 | $30.41 |
| Average True Range (ATR) | 2.22 | 2.10 |
| MACD | -0.02 | -0.83 |
| Stochastic Oscillator | 0.67 | 20.31 |
Price Performance
Historical ComparisonAbout CE Celanese Corporation
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.